Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma

Sara Allstadt Frazier, Daniel S. McKemie, Teri A. Guerrero, Katherine A Skorupski, Carlos O. Rodriguez

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective - To develop a simple extractionless method for detection of rosiglitazone in canine plasma and test the method in a pharmacokinetic study after oral administration of rosiglitazone in dogs. Animals - 3 client-owned dogs with cancer. Procedures - High-performance liquid chromatography - tandem mass spectrometry was performed on canine plasma. The 3 dogs with cancer in the pharmacokinetic study were assessed via physical examination and clinicopathologic evaluation and considered otherwise healthy. Food was withheld for 12 hours, and dogs were administered a single dose (4 mg/m2) of rosiglitazone. Plasma was collected at various times, processed, and analyzed for rosiglitazone. Results - The developed method was robust and detected a minimum of 0.3 ng of rosiglitazone/ mL. Mean ± SD maximum plasma concentration was 205.2 ± 79.1 ng/mL, which occurred at 3 ± 1 hours, and mean ± SD elimination half-life was 1.4 ± 0.4 hours. The area under the plasma rosiglitazone concentration-versus-time curve varied widely among the 3 dogs (mean ± SD, 652.2 ± 351.3 ng/h/mL). Conclusions and Clinical Relevance - A simple extractionless method for detection of rosiglitazone in canine plasma was developed and was validated with excellent sensitivity, accuracy, precision, and recovery. The method enabled unambiguous evaluation and quantitation of rosiglitazone in canine plasma. This method will be useful for pharmacokinetic, bioavailability, or drug-drug interaction studies. Oral rosiglitazone administration was well tolerated in the dogs.

Original languageEnglish (US)
Pages (from-to)263-270
Number of pages8
JournalAmerican Journal of Veterinary Research
Volume72
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

rosiglitazone
Tandem Mass Spectrometry
Canidae
high performance liquid chromatography
High Pressure Liquid Chromatography
dogs
Dogs
pharmacokinetics
Pharmacokinetics
methodology
Oral Administration
oral administration
tandem mass spectrometry
drug interactions
neoplasms

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma. / Allstadt Frazier, Sara; McKemie, Daniel S.; Guerrero, Teri A.; Skorupski, Katherine A; Rodriguez, Carlos O.

In: American Journal of Veterinary Research, Vol. 72, No. 2, 02.2011, p. 263-270.

Research output: Contribution to journalArticle

@article{34e1d193061d4ea4b99d5ea780e33518,
title = "Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma",
abstract = "Objective - To develop a simple extractionless method for detection of rosiglitazone in canine plasma and test the method in a pharmacokinetic study after oral administration of rosiglitazone in dogs. Animals - 3 client-owned dogs with cancer. Procedures - High-performance liquid chromatography - tandem mass spectrometry was performed on canine plasma. The 3 dogs with cancer in the pharmacokinetic study were assessed via physical examination and clinicopathologic evaluation and considered otherwise healthy. Food was withheld for 12 hours, and dogs were administered a single dose (4 mg/m2) of rosiglitazone. Plasma was collected at various times, processed, and analyzed for rosiglitazone. Results - The developed method was robust and detected a minimum of 0.3 ng of rosiglitazone/ mL. Mean ± SD maximum plasma concentration was 205.2 ± 79.1 ng/mL, which occurred at 3 ± 1 hours, and mean ± SD elimination half-life was 1.4 ± 0.4 hours. The area under the plasma rosiglitazone concentration-versus-time curve varied widely among the 3 dogs (mean ± SD, 652.2 ± 351.3 ng/h/mL). Conclusions and Clinical Relevance - A simple extractionless method for detection of rosiglitazone in canine plasma was developed and was validated with excellent sensitivity, accuracy, precision, and recovery. The method enabled unambiguous evaluation and quantitation of rosiglitazone in canine plasma. This method will be useful for pharmacokinetic, bioavailability, or drug-drug interaction studies. Oral rosiglitazone administration was well tolerated in the dogs.",
author = "{Allstadt Frazier}, Sara and McKemie, {Daniel S.} and Guerrero, {Teri A.} and Skorupski, {Katherine A} and Rodriguez, {Carlos O.}",
year = "2011",
month = "2",
doi = "10.2460/ajvr.72.2.263",
language = "English (US)",
volume = "72",
pages = "263--270",
journal = "American Journal of Veterinary Research",
issn = "0002-9645",
publisher = "American Veterinary Medical Association",
number = "2",

}

TY - JOUR

T1 - Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma

AU - Allstadt Frazier, Sara

AU - McKemie, Daniel S.

AU - Guerrero, Teri A.

AU - Skorupski, Katherine A

AU - Rodriguez, Carlos O.

PY - 2011/2

Y1 - 2011/2

N2 - Objective - To develop a simple extractionless method for detection of rosiglitazone in canine plasma and test the method in a pharmacokinetic study after oral administration of rosiglitazone in dogs. Animals - 3 client-owned dogs with cancer. Procedures - High-performance liquid chromatography - tandem mass spectrometry was performed on canine plasma. The 3 dogs with cancer in the pharmacokinetic study were assessed via physical examination and clinicopathologic evaluation and considered otherwise healthy. Food was withheld for 12 hours, and dogs were administered a single dose (4 mg/m2) of rosiglitazone. Plasma was collected at various times, processed, and analyzed for rosiglitazone. Results - The developed method was robust and detected a minimum of 0.3 ng of rosiglitazone/ mL. Mean ± SD maximum plasma concentration was 205.2 ± 79.1 ng/mL, which occurred at 3 ± 1 hours, and mean ± SD elimination half-life was 1.4 ± 0.4 hours. The area under the plasma rosiglitazone concentration-versus-time curve varied widely among the 3 dogs (mean ± SD, 652.2 ± 351.3 ng/h/mL). Conclusions and Clinical Relevance - A simple extractionless method for detection of rosiglitazone in canine plasma was developed and was validated with excellent sensitivity, accuracy, precision, and recovery. The method enabled unambiguous evaluation and quantitation of rosiglitazone in canine plasma. This method will be useful for pharmacokinetic, bioavailability, or drug-drug interaction studies. Oral rosiglitazone administration was well tolerated in the dogs.

AB - Objective - To develop a simple extractionless method for detection of rosiglitazone in canine plasma and test the method in a pharmacokinetic study after oral administration of rosiglitazone in dogs. Animals - 3 client-owned dogs with cancer. Procedures - High-performance liquid chromatography - tandem mass spectrometry was performed on canine plasma. The 3 dogs with cancer in the pharmacokinetic study were assessed via physical examination and clinicopathologic evaluation and considered otherwise healthy. Food was withheld for 12 hours, and dogs were administered a single dose (4 mg/m2) of rosiglitazone. Plasma was collected at various times, processed, and analyzed for rosiglitazone. Results - The developed method was robust and detected a minimum of 0.3 ng of rosiglitazone/ mL. Mean ± SD maximum plasma concentration was 205.2 ± 79.1 ng/mL, which occurred at 3 ± 1 hours, and mean ± SD elimination half-life was 1.4 ± 0.4 hours. The area under the plasma rosiglitazone concentration-versus-time curve varied widely among the 3 dogs (mean ± SD, 652.2 ± 351.3 ng/h/mL). Conclusions and Clinical Relevance - A simple extractionless method for detection of rosiglitazone in canine plasma was developed and was validated with excellent sensitivity, accuracy, precision, and recovery. The method enabled unambiguous evaluation and quantitation of rosiglitazone in canine plasma. This method will be useful for pharmacokinetic, bioavailability, or drug-drug interaction studies. Oral rosiglitazone administration was well tolerated in the dogs.

UR - http://www.scopus.com/inward/record.url?scp=79951921346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951921346&partnerID=8YFLogxK

U2 - 10.2460/ajvr.72.2.263

DO - 10.2460/ajvr.72.2.263

M3 - Article

C2 - 21281203

AN - SCOPUS:79951921346

VL - 72

SP - 263

EP - 270

JO - American Journal of Veterinary Research

JF - American Journal of Veterinary Research

SN - 0002-9645

IS - 2

ER -